MedTrace Logo

Pilot Study of Somatostatin Receptor Imaging in Nasopharyngeal Cancer

NCT03670342 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2020-04-30

No results posted yet for this study

Summary

Hypothesis: To estimate the proportion of locally advanced, recurrent or metastatic nasopharyngeal cancer patients which show high somatostatin receptor density (SUVmax \>10) on Ga-68 DOTATATE imaging.

Galium-68 DOTATATE: PET imaging will be performed with a PET/CT scanner. Galium-68 DOTATATE will be injected intravenously. Scanning will be performed approximately 60 minutes after the injection.

The standardized uptake value (SUV) will be used in the interpretation of the Ga-68 DOTATATE scans. The values gathered will be used as an estimate of the somatostatin receptor density. A patient will be considered to have an overall high somatostatin receptor density if the average SUVmax of all the representative lesions is more than 10.

Conditions

  • Nasopharyngeal Carcinoma

Sponsors & Collaborators

  • Singapore General Hospital

    collaborator OTHER

  • A*Star

    collaborator OTHER

  • National Cancer Centre, Singapore

    lead OTHER

Principal Investigators

  • Wen Long Nei · National Cancer Centre, Singapore

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-20
Primary Completion
2019-04-15
Completion
2019-04-15

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03670342 on ClinicalTrials.gov